Prism Medico & Pharmacy Limited has announced its unaudited standalone financial results for the quarter ended December 31, 2025, following the board meeting held on February 13, 2026. The company reported a net loss of ₹1.34 lakhs for Q3FY26, compared to a net loss of ₹0.96 lakhs in the corresponding quarter of the previous year.

Financial Performance Overview

The company's financial performance showed mixed results during the third quarter. Revenue from operations declined significantly to ₹7.10 lakhs in Q3FY26 from ₹20.86 lakhs in Q3FY25, representing a substantial year-on-year decrease. Total income, including other income of ₹0.69 lakhs, reached ₹7.79 lakhs compared to ₹21.21 lakhs in the previous year's corresponding quarter.

Expense Analysis and Cost Structure

Total expenses for the quarter amounted to ₹9.13 lakhs, down from ₹22.11 lakhs in Q3FY25. Cost of material consumed decreased to ₹4.25 lakhs from ₹15.22 lakhs year-on-year. Employee benefit expenses remained relatively stable at ₹1.19 lakhs compared to ₹1.13 lakhs in the previous year. Other expenses reduced significantly to ₹3.61 lakhs from ₹5.63 lakhs in Q3FY25.

Year-to-Date Performance

For the nine-month period ended December 31, 2025, the company demonstrated contrasting performance with total income of ₹218.60 lakhs and a net profit of ₹55.91 lakhs. This positive year-to-date performance indicates stronger performance in earlier quarters of the financial year.

Board Meeting Details and Regulatory Compliance

The board meeting was conducted at the company's registered office at Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030, commencing at 01:00 P.M. and concluding at 05:30 P.M. The results were approved by the Board of Directors and have been duly reviewed by the Audit Committee in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Stock Exchange Notifications

Prism Medico and Pharmacy Limited has notified both BSE Limited (Scrip Code: 512217) and Metropolitan Stock Exchange of India Limited (Symbol: PRISMMEI) about the financial results. The company maintains its ISIN as INE730E01016 and operates under CIN: L24100HP2002PLC009299. The results were prepared in accordance with Indian Accounting Standards (Ind AS) and reviewed by auditors Garg Mendiratta & Associates, Chartered Accountants.

Prism Medico & Pharmacy Limited has filed its confirmation certificate under SEBI Depositories Regulations for the quarter ended December 31, 2025. The company submitted the mandatory compliance document to BSE Limited and Metropolitan Stock Exchange of India Limited (MSEI) on January 14, 2026.

Regulatory Compliance Filing

The submission was made pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. The confirmation certificate was issued by the company's Registrar and Share Transfer Agent, Purva Sharegistry (I) Pvt. Ltd., dated January 3, 2026.

Share Dematerialisation Activity

The certificate confirms that no dematerialisation activity took place during the Q3FY26 quarter. The detailed report shows nil entries across all parameters including folio numbers, shareholder names, certificate numbers, distinctive numbers, and shares dematerialised.

Company Information

Prism Medico and Pharmacy Limited is incorporated under CIN L24100HP2002PLC009299 with its registered office located at Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh. The company trades on BSE with scrip code 512217 and on MSEI with symbol PRISMMEDI under ISIN INE730E01016.

RTA Confirmation

Purva Sharegistry (I) Pvt. Ltd., the company's SEBI-registered Category 1 Registrar and Share Transfer Agent (Registration No. INR000001112), confirmed compliance with all regulatory requirements. The RTA verified that securities received for dematerialisation were processed within prescribed timelines and that depositories were substituted as registered owners in the member register as required.